Publicaciones en las que colabora con Rosario Menéndez Villanueva (25)

2023

  1. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)

    The Lancet Respiratory Medicine, Vol. 11, Núm. 7, pp. 637-649

  2. Clinical Outcomes of Critical COVID-19 in HIV-Infected Adults: A Propensity Score Matched Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 11, pp. 772-778

  3. Correction: ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia (Intensive Care Medicine, (2023), 49, 6, (615-632), 10.1007/s00134-023-07033-8)

    Intensive Care Medicine

  4. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia

    European Respiratory Journal, Vol. 61, Núm. 4

  5. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia

    Intensive Care Medicine, Vol. 49, Núm. 6, pp. 615-632

  6. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  7. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia: Development and Validation Study

    Chest, Vol. 163, Núm. 1, pp. 77-88

  8. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

  9. Residual pulmonary infiltrates, symptoms and diffusion impairment at 1-year after severe COVID-19 infection have different associated factors

    Journal of Internal Medicine, Vol. 294, Núm. 1, pp. 69-82

2022

  1. Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis

    Archivos de Bronconeumologia, Vol. 58, Núm. 3, pp. 281-283

  2. Factors Associated With One-Year Mortality in Hospitalised Patients With Exacerbated Bronchiectasis

    Archivos de Bronconeumologia, Vol. 58, Núm. 11, pp. 773-775

  3. Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 41, Núm. 2, pp. 271-279

  4. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

2021

  1. Correction to: Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study (European Journal of Clinical Microbiology & Infectious Diseases, (2020), 39, 8, (1513-1525), 10.1007/s10096-020-03870-3)

    European Journal of Clinical Microbiology and Infectious Diseases

  2. Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)

    Critical Care

  3. Pneumonia

    Nature Reviews Disease Primers, Vol. 7, Núm. 1

  4. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

    Critical Care, Vol. 25, Núm. 1

  5. Understanding the host in the management of pneumonia: An official American thoracic society workshop report

    Annals of the American Thoracic Society, Vol. 18, Núm. 7, pp. 1087-1097

  6. Validation of a prediction score for drug-resistant microorganisms in community-acquired pneumonia

    Annals of the American Thoracic Society, Vol. 18, Núm. 2, pp. 257-265

2020

  1. Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators

    Medical sciences (Basel, Switzerland), Vol. 8, Núm. 1